UNASSIGNED: This review summarizes the patents/applications published in the online databases like Espacenet or World Intellectual Property Organization regarding PROTACs that promote BCR-ABL degradation. Patents will be described mostly in terms of chemical structure, biochemical/pharmacological activities, and potential clinical applications.
UNASSIGNED: The recent discovery of the enormous potential of PROTACs led to the creation of new compounds capable of degrading BCR-ABL for the treatment of CML. Although still in reduced numbers, and in the pre-clinical phase of development, some compounds have already been shown to overcome some of the difficulties presented by conventional BCR-ABL inhibitors, such as the well-known imatinib. Therefore, it is very likely that some of the present PROTACs will enter future CML therapy in the coming years.
■本综述总结了在Espacenet或世界知识产权组织等在线数据库中发布的有关促进BCR-ABL降解的PROTACs的专利/申请。专利将主要在化学结构方面进行描述,生化/药理活性,和潜在的临床应用。
■最近对PROTACs巨大潜力的发现导致产生了能够降解BCR-ABL的新化合物,用于治疗CML。虽然数量仍然减少,在发展的临床前阶段,一些化合物已经被证明可以克服常规BCR-ABL抑制剂带来的一些困难,例如著名的伊马替尼。因此,目前的一些PROTACs很有可能在未来几年进入未来的CML治疗.